-- Duopharma Biotech Berhad ("Duopharma Biotech" or "the Company") recorded strong revenue and profit growth in the first quarter ended 31 March 2025, with revenue rising 36.2% to RM262.74 million compared to RM192.97 million in the same period last year. The revenue growth was driven by good performance across all business sectors, with a notable surge in the supply of insulin as supply regularised to fulfill all outstanding orders coupled with enhanced sales to the public sector. At the same time, industry-wide normalisation of Active Pharmaceutical Ingredient (API) prices to a pre-pandemic level also contributed to profit growth.
The profit before tax (PBT) and profit after tax (PAT) for Q1 FY2025, recorded at RM33.74 million and RM25.64 million respectively, both improved by 67.8% year-on-year. Similarly, the Company achieved robust quarter-on-quarter performance, with Q1 FY2025 revenue growing 35.7% compared to Q4 FY2024, while PBT and PAT rose by 93.4% and 70.0% respectively in the same period.
Leonard Ariff Abdul Shatar, Group Managing Director of Duopharma Biotech Berhad, commented, "The Group is off to a strong start in the first quarter of 2025, driven by sustained growth momentum and operational resilience. We see a favourable domestic market, and are pleased to continue contributing towards strengthening Malaysian healthcare capabilities and community wellness with our comprehensive portfolio of effective and innovative products. Meanwhile, in light of global economic uncertainties, we are vigilant in monitoring for potential impact, while remaining focused on enhancing operational efficiencies, optimising cost management strategies, and adapting to evolving market conditions, to remain competitive in the face of rising costs."
In April 2025, Duopharma HAPI Sdn Bhd, a wholly-owned subsidiary of the Company, received and accepted one Letter of Offer (LOO), and Duopharma Manufacturing (Bangi) Sdn Bhd, a wholly-owned subsidiary of the Company, received one additional LO0 from Pharmaniaga Logistics Sdn Bhd for the supply of pharmaceutical and non-pharmaceutical products under the Ministry of Health Malaysia's Approved Products Purchase List (APPL) to healthcare facilities operated by the Malaysian Government. With these additional LOOS plus the other LOOS received by the Group earlier, the Group is now contracted to supply a total of 100 products with a combined estimated value of approximately RM684.15 million, until 31 December 2026.
During Q1 FY2025, the Group paid a second interim dividend of 2.0 sen per share (2024 corresponding quarter: 1.8 sen) equivalent to RM 19.24 million (2023 corresponding quarter: RM17.32 million) in respect of financial year ended 31 December 2024.
Release ID: 89160180
Google
RSS